ArticlePathogens & immunity2024

Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial.

Katya C Corado et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.